Publicacións en colaboración con investigadores/as de University of California, San Francisco (97)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 10, pp. 2910-2921

  3. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  4. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  5. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

  6. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models

    Neuro-Oncology, Vol. 26, Núm. 8, pp. 1509-1525

2023

  1. An International Expert Delphi Consensus on Defining Textbook Outcome in Liver Surgery (TOLS)

    Annals of Surgery, Vol. 277, Núm. 5, pp. 821-828

  2. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

    JCI Insight, Vol. 8, Núm. 2

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  5. Minimally Invasive Versus Open Liver Resections for Hepatocellular Carcinoma in Patients With Metabolic Syndrome

    Annals of surgery, Vol. 278, Núm. 5, pp. e1041-e1047

  6. Model to predict major complications following liver resection for HCC in patients with metabolic syndrome

    Hepatology, Vol. 77, Núm. 5, pp. 1527-1539

  7. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

    Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378

  8. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

  9. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

2022

  1. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells

    Cell Metabolism, Vol. 34, Núm. 6, pp. 857-873.e9

  2. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293

  3. Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma

    Clinical Cancer Research, Vol. 28, Núm. 16, pp. 3537-3545

  4. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

  5. Impact of COVID-19 Lockdown in Eating Disorders: A Multicentre Collaborative International Study

    Nutrients, Vol. 14, Núm. 1